[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-stage-3-4\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-stage-3-4":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,92,113,138,167,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100607902","phase-2-equol-and-vascular-function-in-women-with-chronic-kidney-disease-100607902",false,"NCT07194590","Equol and Vascular Function in Women With Chronic Kidney Disease","Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD","Inclusion Criteria:\n\n* Postmenopausal women\n* Aged ≥50 years\n* CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL\u002Fmin\u002F1.73m2; stable renal function in the past 3 months)\n* Low habitual intake of soy (soy-related food intake \\\u003C 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)\n* Weight stable in the prior 3 months (\\\u003C2 kg weight change) and willing to remain weight stable throughout the study\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with advanced CKD requiring chronic dialysis\n* Uncontrolled hypertension in CKD group (BP \\>140\u002F90 mmHg)\n* Use of any hormone replacement therapy\n* Allergy and\u002For intolerance to soy or soy-based products\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U\u002FL; ALT: 52 U\u002FL; total bilirubin: 1.3 mg\u002FdL)\n* History of breast cancer\n* Significant co-morbid conditions with a life expectancy of \\\u003C 1 year\n* Current tobacco or nicotine use or history of use in the last 12 months\n* History of kidney transplant\n* History of severe congestive heart failure (i.e., ejection fraction \\\u003C35%)\n* History of hospitalization within the last month\n* Immunosuppressant agents taken in the past 12 months\n* Known malignancy","FEMALE","50 Years",{"count":19,"type":20},74,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH.\n\nEquol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.",[26,27,28,29,30],"Chronic Kidney Disease (Stage 3-4)","Vascular Function","Cognitive Functions","Cerebrovascular Function","Blood Pressure",[32,33,34,35,27],"S-equol","Randomized Controlled Trial","Chronic Kidney Disease","Women's Health","RECRUITING","2026-06-01",{"date":39,"type":40},"2026-06-02","ACTUAL",{"date":42,"type":40},"2026-02-19",{"date":44,"type":20},"2030-11-30",{"name":46,"class":47},"University of Colorado, Denver","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":71,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100623450","screening-for-cardiac-and-cardiac-associated-pathology-using-single-channel-electrocardiogram-100623450","NCT07396792","Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram","Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram Analyzed With Machine Learning Models","Inclusion Criteria:\n\n1. The presence of written informed consent of the patient to participate in the study\n2. Availability of examination data allowing for the verification or exclusion of cardiac and cardiac-associated pathology\n3. Age 18 years old and older\n\nNon-inclusion criteria:\n\n1. Patients with an implanted permanent pacemaker;\n2. ECG changes that prevent spectral analysis;\n3. Conditions that may impair the quality of the ECG recording (Parkinson's disease, essential tremor, etc.);\n4. Conditions that make ECG recording in lead I impossible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs).\n5. Lack of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n1. Poor quality of the ECG recording on a single-channel ECG monitor\n2. Insufficient examination data to verify or exclude cardiac or cardiac-associated pathology;\n3. Patient's unwillingness to continue participating in the study for any reason.",true,"ALL","18 Years",{"count":60,"type":20},4000,"OBSERVATIONAL","It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 4000 patients 18 years old and older in the training sample and 1000 patients over 18 years old in the test sample (the total number of patients is at least 5000 people). Patients will be included in the study if they have undergone a full examination (laboratory, clinical and instrumental), allowing for the verification or exclusion of cardiac and cardiac-associated pathology in accordance with current recommendations. During the course of the study, the authors of the work do not interfere with the above-mentioned scope of the examination, which is carried out on patients in accordance with clinical guidelines. All patients included in the study will undergo ECG recording in standard lead I for 1 minute twice, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform. The result of this study will be the identification of ECG parameters that will correlate with cardiac and cardiac-associated pathology",[64,65,66,67,68,26,69,70],"Arterial Hypertension","Heart Rhythm Disorders","Valvular Heart Diseases","Heart Failure","Diabetes Mellitus","Metabolic Syndrome","Coronary Artery Disease",[72,73,74,75,76,77,78,79,80,81],"Screening","Electrocardiogramm","single-channel electrocardiogram","machine learning models","Coronary artery disease","diabetes mellitus","metabolic syndrome","anemia","hypercholesterolemia","arterial hypertension","NOT_YET_RECRUITING","2026-04-13",{"date":85,"type":40},"2026-04-16",{"date":87,"type":20},"2026-04-01",{"date":89,"type":20},"2028-05-13",{"name":91,"class":47},"I.M. Sechenov First Moscow State Medical University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100630107","phase-1-safety-and-efficacy-of-sc101-via-perirenal-fat-injection-for-resistant-hypertension-in-patients-with-moderate-to-severe-chronic-kidney-disease-100630107","NCT07483372","Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 65 years.\n* Participants with an estimated glomerular filtration rate (eGFR) ≥15 mL\u002Fmin\u002F1.73m\\^2 and \\\u003C40 mL\u002Fmin\u002F1.73m\\^2 during the screening period (eGFR is calculated using the Cockcroft-Gault equation).\n* Diagnosed with resistant hypertension: blood pressure (BP) remains uncontrolled after at least 4 weeks of treatment with at least 3 types of antihypertensive drugs (including one diuretic) at tolerated and sufficient doses, in addition to lifestyle modification. At the end of the screening and run-in period (baseline), resting office systolic BP (OSBP) ≥ 140 mmHg, resting office diastolic BP (ODBP) ≥ 90 mmHg, and 24-hour mean ambulatory systolic BP (MASBP) ≥ 130 mmHg.\n* Received stable doses of antihypertensive drugs for at least 4 weeks prior to screening, and can accept stable doses of antihypertensive drugs for 2 weeks during the run-in period.\n* The inferior perirenal fat volume is judged by the investigator to be sufficient for SC101 injection.\n* Agreement to use effective contraceptive measures throughout the trial (within 1 year after SC101 injection), and women of childbearing potential must have a negative pregnancy test during the screening period.\n* Capable of understanding and voluntarily signing the informed consent form, and able to complete the study in accordance with the protocol requirements.\n\nExclusion Criteria:\n\n* Obvious pseudo-resistant hypertension caused by white-coat effect, incorrect BP measurement, poor medication adherence, use of drugs affecting antihypertensive efficacy, insufficient dosage, unreasonable combination therapy, or secondary hypertension (except obstructive sleep apnea) as judged by the investigator.\n* Confirmed history of secondary hypertension (including but not limited to renal artery stenosis, primary aldosteronism, pheochromocytoma, aortic coarctation, etc.).\n* Congenital renal abnormalities that may affect the safety and\u002For efficacy evaluation of the trial, including but not limited to solitary kidney or polycystic kidney disease.\n* Cardiovascular-related diseases that may affect safety evaluation, including but not limited to: uncontrolled symptomatic tachyarrhythmia or bradyarrhythmia (e.g., untreated persistent atrial fibrillation, second-degree or higher heart block, sick sinus syndrome); congestive heart failure NYHA Class III or IV; myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within the past 6 months; severe structural heart disease (including moderate or higher valvular lesions, cardiomyopathy, congenital heart disease).\n* Abnormal liver function, defined as Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \\> 2 times the Upper Limit of Normal (ULN).\n* Hematological diseases that may affect safety evaluation, including but not limited to anemia (Hemoglobin \\\u003C 90 g\u002FL) or abnormal coagulation function (INR \\> 1.5 or fibrinogen less than the lower limit of normal).\n* Type 1 diabetes mellitus or poorly controlled hyperglycemia at screening (defined as HbA1c ≥ 7.5%).\n* Urinary system diseases requiring surgical intervention at screening.\n* Conditions unable to tolerate perirenal fat injection under local anesthesia, including but not limited to local skin problems or structural abnormalities adjacent to perirenal fat.\n* Contraindications related to anesthetics (such as lidocaine).\n* Life expectancy \\\u003C 1 year.\n* History of malignant tumors (except those cured for more than 5 years without recurrence) or confirmed malignant tumors or precancerous lesions.\n* Known Acquired Immunodeficiency Syndrome (AIDS) or HIV-positive status, or previous diagnosis of immunodeficiency with absolute neutrophil count \\\u003C 1000\u002Fmm\\^3.\n* Active liver disease participants, such as positive HAV antibody, positive HBV markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, HBV DNA quantification), or positive HCV antibody (HCV Ab) and HCV RNA quantification above the detection limit.\n* Positive Syphilis antibody and positive Rapid Plasma Reagin (RPR) test.\n* Vaccination with live (attenuated) vaccines within 4 weeks before screening or planned during the trial.\n* Currently participating in other clinical trials, or received other interventional clinical trial drugs within 3 months prior to enrollment.\n* Currently using corticosteroids or immunosuppressants, where the investigator judges that dose adjustments will be required during the trial.\n* Women who are breastfeeding.\n* Other conditions that the investigator believes may affect compliance or make the participant unsuitable for the study.","65 Years",{"count":100,"type":20},3,[102],"PHASE1","This is a single-center, open-label, exploratory clinical study designed to evaluate the safety and efficacy of a single-session injection of SC101, a small interfering RNA (siRNA) agent, into the perirenal fat. This study plans to enroll 3 participants, aged 18 to 65 years, who have a clinical diagnosis of resistant hypertension and moderate to severe chronic kidney disease (CKD).",[105,26],"Resistant Arterial Hypertension","2026-03-27",{"date":87,"type":40},{"date":106,"type":40},{"date":110,"type":20},"2027-12-31",{"name":112,"class":47},"The First Affiliated Hospital with Nanjing Medical University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":48},"100627121","prospective-analysis-of-self-medication-with-phytotherapy-in-nephropatic-patients-100627121","NCT07444515","Prospective AnalysiS of Self medIcation With phytOtherapy in Nephropatic Patients.","PASSION","Inclusion Criteria:\n\nIndividual:\n\n* Adult\n* Resident of Réunion Island and planning to remain on the island for the year following enrollment\n* Chronic Kidney Disease Stage 3, 4, or 5, not on dialysis\n* Under the care of a nephrologist\n* Able to complete a questionnaire\n* Registered with social security\n\nExclusion Criteria:\n\nIndividual:\n\n* Kidney transplant recipient\n* Adult under guardianship or legal protection\n* Pregnant or breastfeeding women, or women planning a pregnancy during the enrollment period",{"count":121,"type":20},400,[123],"NA","We propose the following hypotheses:\n\n* The use of herbal medicine is common among patients with chronic kidney disease in Réunion island.\n* This use could influence the progression of kidney disease in these patients. To assess the primary inclusion criterion, patients will be easily identified by nephrologists through existing follow-up. The questionnaires will be administered after this early identification by the investigators at each center.\n\nThe primary evaluation criterion is straightforward: it aims to establish an overview of the use of herbal medicine in our patient population. This information is currently unavailable and remains crucial for measuring the extent of the issue. Our secondary criteria will involve more in-depth analysis of this use and an attempt to correlate the use of certain herbs with the rate of progression of kidney disease at one year.\n\nWe targeted patients with moderate to end-stage chronic kidney disease (KDIGO classification 3 to 5), which are the stages typically included in kidney disease studies. Furthermore, these patients are the most likely to experience a greater annual progression of their kidney disease, and the effect of herbs on this progression could be investigated. Transplant patients were not included because they are more aware of the risks of not using herbal medicine due to their use of immunosuppressants.",[26,126],"Chronic Kidney Disease (Stages 4 and 5)",[128],"phytotherapy","2026-02-26",{"date":131,"type":40},"2026-03-03",{"date":133,"type":20},"2026-04-02",{"date":135,"type":20},"2028-07-02",{"name":137,"class":47},"Centre Hospitalier Universitaire de la Réunion",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":48},"100621309","phosphate-assessment-in-chronic-kidney-disease-patients-study-100621309","NCT07368946","Phosphate Assessment in Chronic Kidney Disease Patients Study","A Pilot Feeding Study to Assess Phosphate Overload in Patients With Chronic Kidney Disease","PACK","Inclusion Criteria:\n\n* Men or women aged 18 years or older, of any race\u002Fethnicity\n* Women must either be post-menopausal or have no monthly menstrual cycle\n* Estimated total daily energy expenditure (TDEE) of 1700 - 2700 calories\n* eGFR \\>15 ml\u002Fmin\u002F1.73m2 - \\\u003C 60 ml\u002Fmin\u002F1.73m2 for the CKD group (CKD Stage 3 or Stage 4)\n* eGFR ≥ 60 ml\u002Fmin\u002F1.73m2 and negative urine protein on dipstick test for the non-CKD group\n* English speaking\n\nExclusion Criteria:\n\n* Pregnant, currently breastfeeding, or \\\u003C3 months postpartum\n* Current dialysis or kidney transplant patient\n* Current use of insulin or chemotherapy drugs\n* Smokes cigarettes or uses e-cigarettes (vapes)\n* Uses nicotine products or other recreational drugs\n* Medical history of stroke or myocardial infarction (MI)\n* Medical history of conditions that can affect phosphate metabolism (i.e., uncontrolled thyroid disorder, parathyroid disorder, or gastrointestinal malabsorption disorders \\[Crohn's, ulcerative colitis, and celiac disease\\], cirrhosis)\n* Current use of certain medications that directly alter phosphate levels (i.e., phosphate binders; phosphate supplements, irregular use of iron)\n* Regular use of laxatives\n* Hypo- or hyperphosphatemia (serum phosphate \\\u003C 2.5 or \\> 4.6 mg\u002Fdl)\n* Hypo- or hypercalcemia (serum calcium \\\u003C 8.4 or \\> 10.7 mg\u002Fdl)\n* Severe anemia (hemoglobin \\\u003C 8 g\u002Fdl for women and \\\u003C 9 g\u002Fdl for men)\n* Severe hyperglycemia (serum blood glucose \\> 300 mg\u002Fdl)\n* Body weight less than \\\u003C110 lbs (due to risk for phlebotomy-induced anemia)\n* Received a blood transfusion in the last four months\n* Extreme hypertension as demonstrated by a blood pressure \\> 180\u002F120 as the average of 3 blood pressures taken during the screening\u002Fbaseline, or extremely low blood pressure \\\u003C 80\u002F50\n* Unwilling or unable to eat study meals\n* Lack of access to a functional refrigerator or freezer\n* Lack of access to a microwave or conventional oven\n* On low potassium diet\n* On low phosphate diet\n* Specific dietary restrictions (i.e. vegetarian, vegan, ketogenic, etc.)\n* Food allergies including but not limited to milk, egg, soy, nuts, shellfish, and wheat or gluten\n* Allergic to sodium phosphate\n* Unable or unwilling to complete urinary sample collection or food diaries\n* Unable or unwilling to provide informed consent\n* Unable to read or speak English\n* Participant in other conflict clinical trial\n* Unable to complete the study measurements\n* Unsafe to participate in this study per investigator's judgement",{"count":147,"type":20},60,[123],"The proposed pilot feeding study aims to explore novel pathways in phosphate metabolism and identify new biomarkers, as well as to develop a compound index for assessing phosphate overload with high validity and reliability.\n\nInvestigators will address the following specific aims: 1). To explore novel pathways of phosphate metabolism and assess the influence of CKD status on these metabolic pathways. 2). To identify novel biomarkers for phosphate overload that reflect changes in dietary phosphorus intake. 3). To develop a compound phosphate overload index that measures dietary phosphorus intake with high validity and reliability.\n\nThis study will provide novel insights into phosphate metabolism and the assessment of phosphate overload in CKD patients. This investigation aims to provide preliminary data to further studies for the development of reliable biomarkers in CKD patients, which could contribute significantly to early interventions and improve health outcomes.",[26,151],"Chronic Kidney Disease Mineral and Bone Disorder",[153,154,155,156,157],"chronic kidney disease","study diet","feeding study","pilot","oral phosphate feeding","2026-01-26",{"date":160,"type":40},"2026-01-28",{"date":162,"type":40},"2025-05-09",{"date":164,"type":20},"2026-12-31",{"name":166,"class":47},"University of Texas Southwestern Medical Center",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":57,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":191,"locationsCount":48},"100609089","ak-guard-pilot-study-in-chronic-kidney-disease-outpatient-diagnostic-accuracy-and-remote-monitoring-100609089","NCT07210021","AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring","Diagnostic Accuracy, Usability, Patient Compliance, and System Reliability of the AK+ Guard™ ECG Application for Hyperkalemia Prediction in Ambulatory Chronic Kidney Disease Patients (Outpatient and Remote Monitoring Arms)","Inclusion Criteria:\n\n(Arm 2A - Outpatient Diagnostic Accuracy)\n\n* Age 22 years or older\n* CKD stages III-IV managed at Central Jersey Kidney Care outpatient clinic\n* Scheduled outpatient serum potassium laboratory test\n* On RAASi therapy or documented hyperkalemia (K+ ≥ 5.5 mmol\u002FL) within the past 12 months\n* Able to provide written informed consent\n\n(Arm 2B - Remote Patient Monitoring)\n\n* Completion of Arm 2A visit\n* Owns an iPhone compatible with the study application\n\nExclusion Criteria (Both arms):\n\n* Age 21 years or younger\n* Pacemaker or implantable cardioverter defibrillator\n* Pre existing Left Bundle Branch Block (LBBB), Right Bundle Branch Block (RBBB), Intraventricular Conduction Delay (IVCD), or clinically significant hypocalcemia\n* Potassium lowering treatment administered before Lead I ECG acquisition\n* Trauma, acute events, or active interventions altering potassium homeostasis\n* Physical limitation precluding ECG acquisition","22 Years",{"count":176,"type":20},50,"The goal of this observational pilot study is to evaluate the investigational AK+ Guard™ software as a medical device (SaMD) for detection of moderate to severe hyperkalemia (serum potassium (K+) ≥ 6.5 mmol\u002FL) in adults with chronic kidney disease (CKD).\n\nStudy objectives are:\n\n* Arm 2A (Outpatient Diagnostic Accuracy): To generate a preliminary, real-world signal of the diagnostic performance of AK+ Guard™ when used in an ambulatory CKD cohort for identifying clinically significant hyperkalemia episodes (serum K+ ≥ 6.5 mmol\u002FL) at the time of an outpatient laboratory draw.\n* Arm 2B (Remote Patient Monitoring): To assess participant compliance, usability, and end-to-end system reliability of AK+ Guard™ when deployed for daily remote monitoring of CKD patients outside the clinical environment for up to four weeks.",[179,26],"Hyperkalemia",[181,182,183,153,184],"hyperkalemia","ambulatory CKD","CKD","ECG","2025-10-14",{"date":187,"type":40},"2025-10-16",{"date":185,"type":40},{"date":190,"type":20},"2025-11-28",{"name":192,"class":193},"AccurKardia, Inc.","INDUSTRY",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":207,"conditions":208,"keywords":214,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":48},"100607373","phase-4-ace-reno-pico-cell-matrix-and-its-effect-on-egfr-in-chronic-kidney-diseases-100607373","NCT07187713","ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases","ACE Reno, Effect of Pico Cell Matrix on Patients With Micro-albuminuria, Proteinuria or CKD (of Any Degree) Due to Diabetes Mellitus, Autoimmune, Miscellaneous Aetiology","ACE Reno","Inclusion Criteria:\n\n* Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi\u002FARB, SGLT2i, or MRA allowed.\n\nExclusion Criteria:\n\n* Recent kidney transplant (\\\u003C12 months). Uncontrolled acute infection or unstable autoimmune disease. Pregnancy or lactation. Known hypersensitivity to study components.","80 Years",{"count":204,"type":20},300,[206],"PHASE4","This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria\u002Fproteinuria and stabilizes kidney function in participants with nephropathy due to diabetes, hypertension, autoimmune disease, reflux\u002FUTI, chronic glomerulonephritis, unknown etiology, pre-dialysis CKD, or post-transplant proteinuria.\n\nNephropathy remains a global health burden, with \\~9-10% of the population affected by chronic kidney disease (CKD), equating to \\>750 million individuals worldwide. The socioeconomic costs are substantial: in England CKD costs \\~£7 billion annually, projected to rise to \\~£14 billion by 2033; in Malaysia, prevalence rose from 9% to 15.5% within 7 years; in Egypt, CKD imposes heavy familial and financial burdens, especially for pediatric patients; in Turkey, CKD is among the top causes of disability, linked to the rising tide of diabetes, obesity, and hypertension.\n\nACE Reno is designed to address multiple drivers of CKD progression - glomerulosclerosis, fibrosis, endothelial dysfunction, and maladaptive RAAS\u002Faldosterone signaling - through its peptide components that mimic antifibrotic (BMP-7, HGF, Klotho-like) and vasodilatory\u002FcGMP-mediated (natriuretic peptide-like) pathways.",[209,210,34,211,26,126,212,213],"Hypertensive Nephropathy","Auto Immune Disorders","Chronc Kidney Disease Stage 5","Microalbuminuria","Diabetic Nephropathies",[153,215,216],"ckd","nephropathy","2025-09-19",{"date":219,"type":40},"2025-09-23",{"date":221,"type":20},"2025-09-20",{"date":164,"type":20},{"name":224,"class":193},"Ace Cells Lab Limited"]